243 related articles for article (PubMed ID: 21957290)
1. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages.
Koning FA; Goujon C; Bauby H; Malim MH
J Virol; 2011 Dec; 85(24):13448-52. PubMed ID: 21957290
[TBL] [Abstract][Full Text] [Related]
2. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
3. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
4. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation.
Wang Z; Wakae K; Kitamura K; Aoyama S; Liu G; Koura M; Monjurul AM; Kukimoto I; Muramatsu M
J Virol; 2014 Jan; 88(2):1308-17. PubMed ID: 24227842
[TBL] [Abstract][Full Text] [Related]
6. Reversible Human Immunodeficiency Virus Type-1 Latency in Primary Human Monocyte-Derived Macrophages Induced by Sustained M1 Polarization.
Graziano F; Aimola G; Forlani G; Turrini F; Accolla RS; Vicenzi E; Poli G
Sci Rep; 2018 Sep; 8(1):14249. PubMed ID: 30250078
[TBL] [Abstract][Full Text] [Related]
7. Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation.
Sabbatucci M; Covino DA; Purificato C; Mallano A; Federico M; Lu J; Rinaldi AO; Pellegrini M; Bona R; Michelini Z; Cara A; Vella S; Gessani S; Andreotti M; Fantuzzi L
Retrovirology; 2015 Jan; 12():4. PubMed ID: 25608886
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon.
Greenwell-Wild T; Vázquez N; Jin W; Rangel Z; Munson PJ; Wahl SM
Blood; 2009 Aug; 114(9):1864-74. PubMed ID: 19556424
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral APOBEC3 cytidine deaminases alter HIV-1 provirus integration site profiles.
Ajoge HO; Renner TM; Bélanger K; Greig M; Dankar S; Kohio HP; Coleman MD; Ndashimye E; Arts EJ; Langlois MA; Barr SD
Nat Commun; 2023 Jan; 14(1):16. PubMed ID: 36627271
[TBL] [Abstract][Full Text] [Related]
10. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.
Suspène R; Guétard D; Henry M; Sommer P; Wain-Hobson S; Vartanian JP
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8321-6. PubMed ID: 15919829
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
12. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
[TBL] [Abstract][Full Text] [Related]
13. Human APOBEC3 Variations and Viral Infection.
Sadeghpour S; Khodaee S; Rahnama M; Rahimi H; Ebrahimi D
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372572
[TBL] [Abstract][Full Text] [Related]
14. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
15. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
16. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
Yu Q; Chen D; König R; Mariani R; Unutmaz D; Landau NR
J Biol Chem; 2004 Dec; 279(51):53379-86. PubMed ID: 15466872
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
19. Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation.
Delviks-Frankenberry KA; Nikolaitchik OA; Burdick RC; Gorelick RJ; Keele BF; Hu WS; Pathak VK
PLoS Pathog; 2016 May; 12(5):e1005646. PubMed ID: 27186986
[TBL] [Abstract][Full Text] [Related]
20. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
